Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 79

Sort by

Sort Order Select

Journal Articles

A Phase II Study of Dasatinib and Dexamethasone As Primary Therapy Followed By Transplantation for Adults with Newly Diagnosed Ph/ BCR-ABL1 -Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Final Results of Alliance/CALGB Study 10701

Matthew J. Wieduwilt, MD PhD, Jun Yin, PhD, Meir Wetzler, MD, Geoffrey L. Uy, MD, Bayard L. Powell, MD, Jonathan E. Kolitz, MD, Michaela Liedtke, MD, Wendy Stock, MD, Jan H Beumer, Ryan J. Mattison, MD, Elizabeth Storrick, Steven Devine, Scott E. Smith, MD PhD, Richard M. Stone, MD, Richard A. Larson, MD

Blood (2018) 132 (Supplement 1): 309.

https://doi.org/10.1182/blood-2018-99-120029

Published: 2018

Journal Articles

Efficacy and Safety of Two Comparable Single Low Doses of Rasburicase Followed By Allopurinol in Adult Patients with Acute Leukemia

Pankit Vachhani, MD, Craig Freyer, PharmD, BCOP, Jeffrey Baron, PharmD, BCOP, Austin Miller, PhD, Meir Wetzler, MD, James E. Thompson, MD, Elizabeth A. Griffiths, MD, Eunice S. Wang, MD

Blood (2017) 130 (Supplement 1): 5052.

https://doi.org/10.1182/blood.V130.Suppl_1.5052.5052

Published: 2017

Journal Articles

A Phase II Study of Dasatinib and Dexamethasone As Primary Therapy Followed By Hematopoietic Cell Transplantation for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: CALGB Study 10701 (Alliance)

Matthew J. Wieduwilt, MD PhD, Jun Yin, PhD, Meir Wetzler, MD, Geoffrey L. Uy, MD, Bayard L Powell, MD, Jonathan E. Kolitz, MD, Michaela Liedtke, MD, Wendy Stock, MD, Jan H. Beumer, PharmD, PhD, Ryan J. Mattison, MD, Alese Halvorson, Steven M. Devine, MD, Scott Smith, MD PhD, Richard M. Stone, MD, Richard A. Larson, MD

Blood (2016) 128 (22): 2782.

https://doi.org/10.1182/blood.V128.22.2782.2782

Published: 2016

Journal Articles

Functional Genomics and Computational Approaches Identify Novel Small Molecules Targeting Quiescent Leukemia Stem Cells

Costakis Frangou, PhD, Jason Den Haese, PhD, Jordan Warunek, Scott Portwood, MS, MBA, Norma J Nowak, PhD, Andrei V Gudkov, PhD, Katerina Gurova, PhD, Meir Wetzler, MD, Eunice S. Wang, MD

Blood (2015) 126 (23): 1391.

https://doi.org/10.1182/blood.V126.23.1391.1391

Published: 2015

Journal Articles

Adding KIT Inhibitor Dasatinib (DAS) to Chemotherapy Overcomes the Negative Impact of KIT Mutation/over-Expression in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Results from CALGB 10801 (Alliance)

Guido Marcucci, MD, Susan Geyer, PhD, Weiqiang Zhao, MD PhD, Andrew J Caroll, PhD, Donna Bucci, Geoffrey L. Uy, MD, William Blum, MD, Timothy Pardee, MD PhD, Meir Wetzler, MD, Wendy Stock, MD, Jonathan E. Kolitz, MD, Ann-Kathrin Eisfeld, MD, Clara D. Bloomfield, MD, Richard M. Stone, MD, Richard A. Larson

Blood (2014) 124 (21): 8.

https://doi.org/10.1182/blood.V124.21.8.8

Published: 2014

Journal Articles

Single Agent Tamibarotene Has Activity in Acute Promyelocytic Leukemia Patients Previously Treated with ATRA and Arsenic Trioxide, but Does Not Produce Durable Responses

David Sanford, MD, Francesco LoCoco, MD, Miguel A. Sanz, MD PhD, Eros Di Bona, MD, Steven Coutre, MD, Jessica K. Altman, MD, Meir Wetzler, MD, Steven L. Allen, MD, Farhad Ravandi, MD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD

Blood (2014) 124 (21): 3751.

https://doi.org/10.1182/blood.V124.21.3751.3751

Published: 2014

Journal Articles

Presence of Isocitrate Dehydrogenase (IDH) Mutations May Predict Clinical Response to Hypomethylating Agents in Patients with Acute Myeloid Leukemia (AML)

Elizabeth A. Griffiths, MD, Brandon Carter-Cooper, BS, Seda Tolu, BS, Laurie A Ford, BS, CCRC, Rena G. Lapidus, PhD, Meir Wetzler, MD, Eunice S. Wang, MD, Arash Etemadi, MD PhD, Ashkan Emadi, MD, PhD

Blood (2014) 124 (21): 3724.

https://doi.org/10.1182/blood.V124.21.3724.3724

Published: 2014

Journal Articles

A Phase I Study of Lenalidomide and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia

Elizabeth A. Griffiths, MD, William Brady, Wei Tan, Carlos E Vigil, MD, James E. Thompson, MD, Laurie A Ford, BS, CCRC, Noelle M Dickey, BS, Jill Sperrazza, BS, Eunice S. Wang, MD, Meir Wetzler, MD

Blood (2014) 124 (21): 2318.

https://doi.org/10.1182/blood.V124.21.2318.2318

Published: 2014

Journal Articles

Decitabine and Sorafenib Therapy in Patients with FLT3-ITD Mutant Acute Myeloid Leukemia Is Associated with High Response Rates—a Single Institute Experience

Monica Reddy Muppidi, MD, Elizabeth A. Griffiths, MD, James E. Thompson, MD, Laurie A Ford, BS, CCRC, Craig W Freyer, Pharm.D., BCOP, Meir Wetzler, MD, Eunice S. Wang, MD

Blood (2014) 124 (21): 5284.

https://doi.org/10.1182/blood.V124.21.5284.5284

Published: 2014

Journal Articles

Minimal Residual Disease Sensitivity in Patients with Pre-B Cell Acute Lymphoblastic Leukemia Using Gemstone Analysis Method

Muaz Alrazzak, MD, Beth Hill, PhD, Elizabeth A. Griffiths, MD, Eunice S. Wang, MD, Meir Wetzler, MD, Paul K Walace, PhD

Blood (2014) 124 (21): 5348.

https://doi.org/10.1182/blood.V124.21.5348.5348

Published: 2014

Journal Articles

25(OH) Vitamin D 3 Affects Acute Myeloid Leukemia Cell Proliferation

Costa G Frangou, PhD, Jason Den Haese, Norma Nowak, PhD, Candace S. Johnson, PhD, Donald Trump, MD, FACP, Meir Wetzler, MD

Blood (2013) 122 (21): 5026.

https://doi.org/10.1182/blood.V122.21.5026.5026

Published: 2013

Journal Articles

Patients Treated With Decitabine Demonstrate Changes In β-Catenin Localization From The Nucleus To The Cytoplasm In Circulating Blasts

Michelle Golding, Benjamin E Paluch, BS, Pragya Srivastava, PhD, Song Liu, PhD, Qiang Hu, PhD, Meir Wetzler, MD, Michael Nemeth, Elizabeth A. Griffiths, MD

Blood (2013) 122 (21): 3956.

https://doi.org/10.1182/blood.V122.21.3956.3956

Published: 2013

Journal Articles

Decitabine Is More Cost Effective Than Standard Conventional Induction Therapy In Elderly Acute Myeloid Leukemia Patients

Nicolas Batty, MD, Samuel Wiles, Mathew Kabalan, Rohit Sharma, MD, Joseph Shatzel, MD, Jonathan Pang, David Yi, Iris Alatovic, Sana Saif, MD, Deepika Narasimha, Joseph LaPenna, Anthony Troitino, MD, Kristopher Attwood, MS, Yong Yin, PhD, Meir Wetzler, MD

Blood (2013) 122 (21): 2699.

https://doi.org/10.1182/blood.V122.21.2699.2699

Published: 2013

Journal Articles

Clinical and Biologic Effects Of The Angiopoietin 1/2 Neutralizing Peptibody, Trebananib (AMG 386), In Acute Myeloid Leukemia Patients

Eunice S. Wang, MD, Gerald Fetterly, PhD, William Brady, Wei Tan, Jessica Greene, Allison Gaudy, Carlos E Vigil, MD, Jason H. Mendler, MD, PhD, Michael W. Becker, MD, Kristen O'Dwyer, MD, Jane L. Liesveld, MD, Meir Wetzler, MD

Blood (2013) 122 (21): 2701.

https://doi.org/10.1182/blood.V122.21.2701.2701

Published: 2013

Journal Articles

Final Analysis Of The Efficacy and Tolerability Of Subcutaneous Omacetaxine Mepesuccinate, ≥24 Months After First Dose, In Patients With Chronic Phase (CP) Or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML)

Jorge E. Cortes, MD, Meir Wetzler, MD, Jeffrey H. Lipton, MD, PhD, H. Jean Khoury, MD, Patricia Kropf, MD, Mauricette Michallet, MD, PhD, Michele Baccarani, MD, Delphine Rea, MD, PhD, Charles Chuah, MD, Raghunadharao Digumarti, MD, Purvish M. Parikh, MD, PhD, Elizabeth Li, MS, Mihaela C. Munteanu, MS, Peter D. Brown, DPhil, Franck E. Nicolini, MD, PhD

Blood (2013) 122 (21): 2743.

https://doi.org/10.1182/blood.V122.21.2743.2743

Published: 2013

Journal Articles

A Randomized Phase II Study Of Sapacitabine In MDS Refractory To Hypomethylating Agents

Guillermo Garcia-Manero, MD, Selina M Luger, MD, Stuart Goldberg, MD, Jessica K Altman, MD, Martha Arellano, MD, Meir Wetzler, MD, Karen Seiter, MD, Judy Chiao, MD, Hagop M Kantarjian, MD

Blood (2013) 122 (21): 2752.

https://doi.org/10.1182/blood.V122.21.2752.2752

Published: 2013

Journal Articles

Adding The KIT Inhibitor Dasatinib (DAS) To Standard Induction and Consolidation Therapy For Newly Diagnosed Patients (pts) With Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Initial Results Of The CALGB 10801 (Alliance) Study

Guido Marcucci, MD, Susan Geyer, PhD, John Zhao, MD, PhD, Andrew J Caroll, PhD, Donna Bucci, Ravi Vij, MD, William Blum, MD, Timothy Pardee, MD, PhD, Meir Wetzler, MD, Wendy Stock, MD, Clara D. Bloomfield, MD, Richard A. Larson, MD, Richard M. Stone, MD

Blood (2013) 122 (21): 357.

https://doi.org/10.1182/blood.V122.21.357.357

Published: 2013

Journal Articles

Evolution Of Acute Myelogenous Leukemia Stem Cell Properties Following Treatment and Progression

TzuChieh Ho, BS, Mark W LaMere, BS, Kristen O'Dwyer, MD, Jason H. Mendler, MD, PhD, Jane L. Liesveld, MD, Meir Wetzler, MD, Eunice S. Wang, MD, Monica L. Guzman, PhD, Craig T. Jordan, PhD, Michael W. Becker, MD

Blood (2013) 122 (21): 883.

https://doi.org/10.1182/blood.V122.21.883.883

Published: 2013

Journal Articles

Comparison Of Epigenetic Versus Intensive Chemotherapy For Newly Diagnosed Acute Myeloid Leukemia Patients ≥60 Years Old: The Roswell Park Experience

Neha Gupta, MD, Shipra Gandhi, MD, Austin Miller, PhD, Laurie A Ford, BS, CCRC, Elizabeth A. Griffiths, MD, James E. Thompson, MD, Meir Wetzler, MD, Eunice S. Wang, MD

Blood (2013) 122 (21): 1445.

https://doi.org/10.1182/blood.V122.21.1445.1445

Published: 2013

Journal Articles

Pooled Analysis of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles.

Farhad Ravandi, MD, Tapan M. Kadia, M.D., Gautam Borthakur, M.D., William G. Wierda, MD, PhD, Stuart L. Goldberg, MD, Meir Wetzler, MD, Parameswaran Venugopal, MD, Karen Seiter, MD, Judy Chiao, MD, Hagop M. Kantarjian, MD

Blood (2012) 120 (21): 2630.

https://doi.org/10.1182/blood.V120.21.2630.2630

Published: 2012

NARROW

A Phase II Study of Dasatinib and Dexamethasone As Primary Therapy Followed By Transplantation for Adults with Newly Diagnosed Ph/ BCR-ABL1 -Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Final Results of Alliance/CALGB Study 10701

Efficacy and Safety of Two Comparable Single Low Doses of Rasburicase Followed By Allopurinol in Adult Patients with Acute Leukemia

A Phase II Study of Dasatinib and Dexamethasone As Primary Therapy Followed By Hematopoietic Cell Transplantation for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: CALGB Study 10701 (Alliance)

Functional Genomics and Computational Approaches Identify Novel Small Molecules Targeting Quiescent Leukemia Stem Cells

Adding KIT Inhibitor Dasatinib (DAS) to Chemotherapy Overcomes the Negative Impact of KIT Mutation/over-Expression in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Results from CALGB 10801 (Alliance)

Single Agent Tamibarotene Has Activity in Acute Promyelocytic Leukemia Patients Previously Treated with ATRA and Arsenic Trioxide, but Does Not Produce Durable Responses

Presence of Isocitrate Dehydrogenase (IDH) Mutations May Predict Clinical Response to Hypomethylating Agents in Patients with Acute Myeloid Leukemia (AML)

A Phase I Study of Lenalidomide and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia

Decitabine and Sorafenib Therapy in Patients with FLT3-ITD Mutant Acute Myeloid Leukemia Is Associated with High Response Rates—a Single Institute Experience

Minimal Residual Disease Sensitivity in Patients with Pre-B Cell Acute Lymphoblastic Leukemia Using Gemstone Analysis Method

25(OH) Vitamin D 3 Affects Acute Myeloid Leukemia Cell Proliferation

Patients Treated With Decitabine Demonstrate Changes In β-Catenin Localization From The Nucleus To The Cytoplasm In Circulating Blasts

Decitabine Is More Cost Effective Than Standard Conventional Induction Therapy In Elderly Acute Myeloid Leukemia Patients

Clinical and Biologic Effects Of The Angiopoietin 1/2 Neutralizing Peptibody, Trebananib (AMG 386), In Acute Myeloid Leukemia Patients

Final Analysis Of The Efficacy and Tolerability Of Subcutaneous Omacetaxine Mepesuccinate, ≥24 Months After First Dose, In Patients With Chronic Phase (CP) Or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML)

A Randomized Phase II Study Of Sapacitabine In MDS Refractory To Hypomethylating Agents

Adding The KIT Inhibitor Dasatinib (DAS) To Standard Induction and Consolidation Therapy For Newly Diagnosed Patients (pts) With Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Initial Results Of The CALGB 10801 (Alliance) Study

Evolution Of Acute Myelogenous Leukemia Stem Cell Properties Following Treatment and Progression

Comparison Of Epigenetic Versus Intensive Chemotherapy For Newly Diagnosed Acute Myeloid Leukemia Patients ≥60 Years Old: The Roswell Park Experience

Pooled Analysis of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only